NSE: ATUL | BSE: 500027

Mid-range Performer

Download real time

6575.00 -99.00 (-1.48%)

38.36% Gain from 52W Low

5,702 NSE+BSE Volume

NSE 02 Mar, 2026 10:08 AM (IST)

19,358

Market Cap

High in industry

Beta 1Year

Low volatility

Atul Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ATUL, BSE:500027 Atul Ltd.

Search Inside the pdf :

Atul Ltd.

25 Jan 2026

6575.00

-1.48%

Growth momentum sustains with the performance segment at the core

Buy: Atul Ltd.

Target

Motilal Oswal

Atul (ATLP) reported in-line revenue of INR15.7b (+11% YoY) in 3QFY26. Revenue from the Performance & Other Chemicals segment increased 11% YoY, while the Life Science Chemical segment’s revenue rose 9% YoY.

Atul Ltd. has an average target of 7725.00 from 4 brokers.

Atul Ltd.

19 Jul 2025

6575.00

-1.48%

Muted EBITDA performance in Q1; business mix deteriorates

Hold: Atul Ltd.

ICICI Securities Limited

Atul Ltd’s (Atul) Q1FY26 EBITDA rose just 5.5% YoY at INR 2.4bn, and was hurt from under-performance in standalone business where EBITDA declined 12.5%; entire growth came from subsidiaries (up 93% YoY).

Atul Ltd. is trading above all available SMAs

Atul Ltd.

18 Jul 2025

6575.00

-1.48%

Performance segment leads the recovery

Buy: Atul Ltd.

Target

Motilal Oswal

Atul (ATLP) reported in-line revenue at INR14.78b (+12% YoY) in 1QFY26. Revenue of the Performance & Other Chemicals segment increased 14% YoY, while the Life Science Chemical segment posted 6% YoY growth.

Atul Ltd. is trading above all available SMAs

Atul Ltd.

06 May 2025

6575.00

-1.48%

Capacity in action: Utilization gains to drive earnings; Buy

Buy: Atul Ltd.

Anand Rathi

Atul invested ~Rs20bn over the last three years in setting up capacity (capex matching the cumulative investment over the last decade). In its analyst meet, management highlighted unrealized sales potential of over Rs25bn from recently concluded capex (~Rs17bn) and from previously unutilized capacity (~Rs8bn).

Number of FII/FPI investors decreased from 203 to 173 in Dec 2025 qtr

Atul Ltd.

03 May 2025

6575.00

-1.48%

Stellar bounce-back in FY25; growth expected to continue

Buy: Atul Ltd.

Target

Motilal Oswal

Atul’s (ATLP) 4QFY25 revenue came in line with our expectation. The Life Science Chemicals (LSC) segment’s revenue increased 18% YoY, while the Performance & Other Chemicals (P&OC) segment’s revenue rose 21% YoY.

Atul Ltd. has an average target of 7725.00 from 4 brokers.

Atul Ltd.

23 Apr 2025

6575.00

-1.48%

Ripe for volume growth; cheap valuation, favorable risk-reward

Buy: Atul Ltd.

Emkay

We initiate coverage on Atul with BUY and TP of Rs8,500 (30x Mar-27E EPS). Atul has invested ~Rs20bn over FY22-24 toward capacity expansion in existing products like Liquid Epoxy Resin (50ktpa) and Caustic Soda (300tpd), and in the backward integration of some key products (MCA for 2,4 D).

Number of FII/FPI investors decreased from 203 to 173 in Dec 2025 qtr

Atul Ltd.

26 Jan 2025

6575.00

-1.48%

The Life Science segment continues its stellar performance

Buy: Atul Ltd.

Target

Motilal Oswal

Atul (ATLP) reported revenue 7% above our expectation in 3QFY25. Revenue in the Life Science Chemicals segment increased 23% YoY, while it rose 24% YoY in the Performance & Other Chemicals segment

Atul Ltd. is trading above all available SMAs

Atul Ltd.

13 Nov 2024

6575.00

-1.48%

Signs of recovery evident in financial performance

Buy: Atul Ltd.

Target

Sharekhan

Topline rose 17% y-o-y and 5% q-o-q, with operating Profit of Rs. 243 crore and adjusted
PAT of Rs. 112 Crore surpassing our estimates, attributed to margin enhancements in
LSC and POC.

Atul Ltd. has an average target of 7725.00 from 4 brokers.

Atul Ltd.

27 Oct 2024

6575.00

-1.48%

Impressive show continues in both the business segments

Buy: Atul Ltd.

Target

Motilal Oswal

Atul (ATLP) reported in-line revenue in 2QFY25. Revenue in the Life Science Chemicals segment increased 13% YoY, while it rose 18% YoY in the Performance & Other Chemicals segment.